Joannides R, Moore N, Iacob M, Compagnon P, Bacri A M, Thuillez C
Department of Clinical Pharmacology, Rouen University Hospital, France.
J Hypertens Suppl. 1998 Jan;16(1):S25-9.
To evaluate, in healthy volunteers, the effects of acute administration of two calcium antagonists with different pharmacological profiles, verapamil and amlodipine, on haemodynamics at rest and during exercise.
Six healthy volunteers (aged 20-29 years) were randomly assigned to receive single oral doses of amlodipine (5 mg), slow-release verapamil (240 mg) or a placebo during a double-blind cross-over study. Systolic (SAP), diastolic and mean arterial pressures (measured using a cuff sphygmomanometer), heart rate (HR), cardiac index (CI, bioimpedance), rate-pressure product (SAP x HR), and noradrenaline and adrenaline plasma levels were measured at rest before drug administration, and at rest and during graded bicycle exercise (steps of 50, 100 and 150 W during 3, 3 and 4 min, respectively) started 3 h after drug administration.
At rest arterial pressure, HR, rate-pressure product and catecholamine plasma levels did not change after verapamil or amlodipine administration, whereas CI significantly decreased after verapamil (from 3.9 +/- 0.4 to 3.3 +/- 0.4 l/min per m2) but not after amlodipine (3.9 +/- 0.3 and 4.1 +/- 0.5 l/m per m2) administration. During exercise the increases in SAP and HR were slightly but not significantly higher after amlodipine than after verapamil administration, rate-pressure product and CI were higher after amlodipine (22 +/- 1 x 10(3) mmHg x beats/min and 13 +/- 2 l/min per m2, respectively) than after verapamil (20 +/- 1 x 10(3) mmHg x beats/min and 10 +/- 2 l/min per m2, respectively) administration. Plasma levels of noradrenaline and adrenaline were similar at rest after each treatment and were slightly more increased after amlodipine administration during exercise.
In contrast to amlodipine, verapamil induced a slight myocardial depressive effect at rest and did not potentiate the myocardial effects of the sympathetic stimulation induced by exercise. The myocardial action of verapamil is such as to induce some decrease in myocardial oxygen demand, both at rest and during exercise.
在健康志愿者中评估急性给予两种具有不同药理学特性的钙拮抗剂维拉帕米和氨氯地平对静息及运动时血流动力学的影响。
在一项双盲交叉研究中,6名健康志愿者(年龄20 - 29岁)被随机分配接受单次口服剂量的氨氯地平(5毫克)、缓释维拉帕米(240毫克)或安慰剂。在给药前静息状态下、给药后3小时静息状态以及分级自行车运动期间(分别在3分钟、3分钟和4分钟内以50、100和150瓦的功率递增)测量收缩压(SAP)、舒张压和平均动脉压(使用袖带血压计测量)、心率(HR)、心脏指数(CI,生物阻抗法)、率压乘积(SAP×HR)以及去甲肾上腺素和肾上腺素的血浆水平。
静息时,给予维拉帕米或氨氯地平后动脉压、HR、率压乘积和儿茶酚胺血浆水平均未改变,而给予维拉帕米后CI显著降低(从3.9±0.4降至3.3±0.4升/分钟每平方米),给予氨氯地平后CI未降低(3.9±0.3和4.1±0.5升/分钟每平方米)。运动期间,氨氯地平给药后SAP和HR的升高略高于维拉帕米给药后,但无显著差异,氨氯地平给药后的率压乘积和CI高于维拉帕米给药后(分别为22±¹×10³毫米汞柱×次/分钟和13±²升/分钟每平方米)(分别为20±¹×10³毫米汞柱×次/分钟和10±²升/分钟每平方米)。每次治疗后静息时去甲肾上腺素和肾上腺素的血浆水平相似,运动期间氨氯地平给药后略有升高。
与氨氯地平不同,维拉帕米在静息时可引起轻微的心肌抑制作用,且不增强运动诱导的交感神经刺激的心肌效应。维拉帕米的心肌作用可使静息及运动时心肌需氧量有所降低。